Probuphine (buprenorphine implant)

DRUG5 trials

Sponsors

Titan Pharmaceuticals

Conditions

Opioid DependenceOpioid Dependency

Phase 3

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

CompletedNCT00630201

Titan PharmaceuticalsOpioid Dependence

Start: 2007-10-31End: 2009-02-28Updated: 2018-12-31

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

TerminatedNCT00768482

Titan PharmaceuticalsOpioid Dependence

Start: 2008-09-30End: 2008-12-31Updated: 2018-12-31

Study of Probuphine in Patients With Opioid Dependence

TerminatedNCT00772785

Titan PharmaceuticalsOpioid Dependency

Start: 2008-09-30End: 2009-02-28Updated: 2018-12-31

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

CompletedNCT01114308

Titan PharmaceuticalsOpioid Dependency

Start: 2010-04-30End: 2011-05-31Updated: 2018-12-31

Re-Treatment Study of Probuphine in Opioid Addiction

CompletedNCT01262261

Titan PharmaceuticalsOpioid Dependency

Start: 2010-11-30End: 2011-11-30Updated: 2018-12-31

Related Papers

Long-Term Buprenorphine Implants for Treatment of Opioid Dependence: Safety Outcomes from Two Open-Label Extension Trials

Journal of Addictive Behaviors Therapy & Rehabilitation2017-01-012 citations